Oxford Biomedica (LON:OXB) Announces Earnings Results

Oxford Biomedica (LON:OXB) released its earnings results on Wednesday. The biopharmaceutical company reported GBX (30.39) EPS for the quarter, Digital Look Earnings reports. The company had revenue of GBX 7,985 million for the quarter. Oxford Biomedica had a negative return on equity of 54.51% and a negative net margin of 23.23%.

Oxford Biomedica Trading Up 0.8%

Shares of Oxford Biomedica stock opened at GBX 494 on Friday. The company has a current ratio of 2.21, a quick ratio of 1.67 and a debt-to-equity ratio of 273.08. The company has a fifty day simple moving average of GBX 509.34 and a 200-day simple moving average of GBX 575.10. The stock has a market cap of £597.98 million, a price-to-earnings ratio of -18.35 and a beta of 1.09. Oxford Biomedica has a 12-month low of GBX 420 and a 12-month high of GBX 952.

Insiders Place Their Bets

In related news, insider Roch Doliveux acquired 20,250 shares of the firm’s stock in a transaction on Wednesday, September 23rd. The stock was bought at an average price of GBX 505 per share, for a total transaction of £102,262.50. 43.30% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Royal Bank Of Canada reissued an “outperform” rating and set a GBX 900 price objective on shares of Oxford Biomedica in a research report on Tuesday, September 1st. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 8.27 price target on shares of Oxford Biomedica in a research note on Tuesday, June 2nd. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a GBX 595 price target on shares of Oxford Biomedica in a report on Wednesday, September 2nd. Four equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of GBX 580.85.

Oxford Biomedica Company Profile

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.